Expressing disapproval of the decision by the Supreme Court in Sorrell v. IMS Health Inc.

Disapproves of the majority opinion in Sorrell v. IMS Health Inc., because it puts prescribers at risk of having their prescriber-identifying information sold without their knowledge or consent.

Expresses the belief of the House of Representatives that: (1) the Supreme Court incorrectly applied a heightened First Amendment standard of review to an instance of commercial regulation; (2) the negative impact on a pharmaceutical manufacturer's ability to market its products is outweighed by the interests of patient safety, doctor privacy, and health care costs; and (3) the states have the right to regulate the pharmaceutical industry based on what is best for the health and safety of their residents.